Revolution Medicines to Unveil Phase 3 Daraxonrasib Data After 13.2-Month Pancreatic Cancer Survival
Updated
Updated · PBS NewsHour · May 29
Revolution Medicines to Unveil Phase 3 Daraxonrasib Data After 13.2-Month Pancreatic Cancer Survival
7 articles · Updated · PBS NewsHour · May 29
Sunday’s ASCO presentation in Chicago will give the first full Phase 3 look at daraxonrasib, a once-daily KRAS inhibitor for pancreatic cancer that has drawn cautious optimism from outside experts.
April trial data showed median overall survival of 13.2 months in previously treated patients, versus 6.7 months on standard chemotherapy alone, with more than one-third of a key KRAS-mutant subgroup seeing tumors shrink by at least 30%.
KRAS mutations appear in more than 90% of the most common pancreatic cancers, and researchers say daraxonrasib’s ability to hit multiple KRAS mutations could widen use without mutation-by-mutation screening.
Safety and access remain hurdles: about 30% of patients had severe side effects, 90% developed rash, and doctors say expanded access after the FDA’s April 30 fast-track action still has not translated into broad availability.
Pancreatic cancer’s five-year survival rate is just 3% after it has spread, leaving Sunday’s data as a key test of whether KRAS-targeted drugs can move earlier in treatment or into combination regimens.
After decades of failure, a pill targets the 'undruggable' KRAS gene. Is this the key to treating many other deadly cancers?
This new pill doubles survival but causes severe side effects. Is the promise of more time worth the difficult treatment journey?
Daraxonrasib Achieves 13.2-Month Median Survival in Metastatic Pancreatic Cancer—A New Era for RAS-Targeted Therapy
Overview
Pancreatic cancer is one of the toughest challenges in oncology, with most patients dying within months of diagnosis and only 3 percent surviving five years after the cancer spreads. Each year, it causes over 50,000 deaths in the United States and accounts for about 8 percent of all cancer deaths. Because the outlook for patients with metastatic pancreatic cancer is so poor, there is an urgent need for new treatments that can extend survival and improve quality of life. The report highlights how recent advances are beginning to address this critical need, offering new hope for patients.